Cargando…
The pharmacologic basis for the efficacy of high-dose Ara-C and sequential asparaginase in adult acute myelogenous leukemia.
Dose-related effects of ara-C include overcoming a relative transport impediment in human leukemia cells. This result then allows intracellular metabolism and incorporation into DNA to proceed to the maximum extent possible. In addition, the increased synthesis of ara-CDP-choline associated with the...
Autores principales: | Capizzi, R. L., White, C. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Yale Journal of Biology and Medicine
1988
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2590410/ https://www.ncbi.nlm.nih.gov/pubmed/3163212 |
Ejemplares similares
-
Randomized evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients
por: Dennis, Mike, et al.
Publicado: (2021) -
Optimization of cytarabine (ARA-C) therapy for acute myeloid leukemia
por: Momparler, Richard L
Publicado: (2013) -
Pharmacogenetics of asparaginase in acute lymphoblastic leukemia
por: Abaji, Rachid, et al.
Publicado: (2019) -
Acute Myelogenous Leukemia and Febrile Neutropenia
por: Herbers, Alexandra, et al.
Publicado: (2009) -
The structural basis of BCR-ABL recruitment of GRB2 in chronic myelogenous leukemia
por: Liu, Yonglan, et al.
Publicado: (2022)